Investors in Indivior PLC (INDV) Potential Class Action Lawsuit

NEW YORK, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Investors of Indivior PLC INDV, a specialty pharmaceutical company, have been alerted by Levi & Korsinsky, LLP regarding the filing of a class action lawsuit. The legal complaint addresses allegations of securities fraud related to Indivior's prescription drug business dealing with opioid dependence treatments. Shareholders who have incurred losses due to the company's alleged misrepresentations and omissions are now being offered a chance to join a collective legal effort to seek compensation.

Background on Indivior PLC INDV

Indivior PLC, a company headquartered in North Chesterfield, Virginia, is known for its focus on buprenorphine-based prescription drugs targeted at treating opioid dependence and other accompanying medical conditions. However, recent events have led to considerable concern among its investors.

Details of the Securities Class Action Against INDV

Investors who have experienced financial losses from investment in Indivior PLC's stocks INDV between specified dates are being summoned to participate in a class action lawsuit. The thrust of the case is based on allegations that the company may have misrepresented key financial information influencing investment decisions. The lawsuit represents a collective measure aimed at holding Indivior accountable if they indeed failed to adhere to securities laws by providing accurate and truthful information to the public and their investors.

Any shareholders who have suffered monetary damages from trading in Indivior's shares are encouraged to understand their legal rights and potential recourse in this matter. Taking part in the class action could potentially result in the recovery of lost funds if the court rules in favor of the plaintiffs. The law firm of Levi & Korsinsky is urging affected investors to make contact for more information on the lawsuit and assistance in joining the class action initiative.

Indivior, Lawsuit, Investment